Botox (onabotulinumtoxinA, Allergan), Dysport (abobotulinumtoxinA, Galderma) and Xeomin (incobotulinumtoxinA, Merz) do not have equivalent strain reduction, according to a study of glabellar line treatments. The results, researchers conclude, confirm non-interchangeability of these neurotoxins.
Researchers treated 73 treatment-naive females randomized to 20 units of Botox, 60 units of Dysport or 20 units of Xeomin in the glabella. They imaged patients 4, 14 and 90 days post injection and noted change in average dynamic glabella strain.
The researchers found that at day 4 the Botox group had a 42.1% strain reduction, vs. a 39.4% reduction in the Dysport group and 19.8% reduction in the Xeomin group. By day 14, there was a 66.1% strain reduction in the Botox patients; a 51.4% strain reduction in the Dysport group; and a 42.8% strain reduction among those receiving Xeomin. At day 90, the Botox group had a 43.5% strain reduction, vs. a 38.4% strain reduction among those receiving Dysport and a 25.3% strain reduction in the Xeomin group.
 
 
Register Today!  How to Successfully Open a Medical Spa--Northwest: September 19-20, 2016
How to Successfully Open a Medical Spa--Texas: November 6-7, 2016
Southwest Medical Spa Regulatory Workshop: December 5, 2016